View Clinical Trial (Medical Research Study)


A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee - NCT00981357-66211(Clinical Trial 403430)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Overland Park
State:  
KS
Zip Code: 66211
Conditions: Osteoarthritis, Knee
Purpose: Inactivation of the FAAH (Fatty Acid Amide Hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. PF-04457845 has been shown to inactivate the FAAH enzyme in animals and healthy human volunteers. The purpose of this study is to evaluate whether PF-04457845 can inactivate the FAAH enzyme in patients experiencing pain due to OA and whether this results in these patients experiencing less pain.
Study summary:
Criteria: Inclusion Criteria: - Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray - Subjects must be willing and able to stop all current pain therapy for the duration of study. (Limited and specific pain therapy will be available throughout the study) - Subjects can be male or female between the ages of 18 and 75 years inclusive, but female subjects must not be able become pregnant Exclusion Criteria: - Subjects must not have any condition or medical history that might interfere with their ability to complete the study assessments
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: June 23, 2010
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.